Workflow
Biotechnology Stocks
icon
Search documents
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data (NASDAQ:KURA)
Seeking Alphaยท 2025-12-02 23:36
Core Insights - The article highlights the background and expertise of Brendan, who has a strong foundation in organic synthesis and experience in both pharmaceutical and biotech sectors [1] Group 1: Background and Experience - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck, a major pharmaceutical company, from 2009 to 2013 [1] - His experience includes working with biotech startups such as Theravance and Aspira before joining Caltech [1] Group 2: Entrepreneurial Ventures - Brendan was the first employee and co-founder of 1200 Pharma, which spun out of Caltech and secured significant investment in the 8 figures [1] - He remains an active investor, focusing on market trends, particularly in biotechnology stocks [1]